Dennis Paul

Dr. Paul is co-inventor with Dr. Gould of Targeted Osmotic Lysis (TOL). He is Professor of Pharmacology and Experimental Therapeutics at Louisiana State University Health Sciences Center (LSUHSC) in New Orleans.

Drs. Paul and Gould have had a research collaboration for more than 20 years. Their work initially focused on general concepts and biological principles related to the role played by sodium channels in the mechanisms responsible for pain and diabetic peripheral neuropathy. Their research on sodium channels and sodium pumps led directly to their research on manipulation of these mechanisms in the treatment of advanced cancer.

Dr. Paul's research has also contributed to the understanding of opioid pharmacology and drug-drug interactions. He received his undergraduate training at the University of Cincinnati, his Ph.D. from the University of British Columbia, and completed Post-Doctoral training at the Memorial Sloan Kettering Cancer Center. He has served on scientific advisory boards for Xanadyne Pharmaceuticals and St. Charles Pharmaceuticals.